Published March 10, 2021 | Version v1
Report Open

RETURNING INDIVIDUAL CLINICAL TRIAL DATA BACK TO PARTICIPANTS

  • 1. ReveraGen Biopharma
  • 2. World Duchenne Organisation
  • 3. Ceratium Ltd

Description

A white paper addressing the ethical and technical challenges of returning meaningful individual clinical trial results to trial participants

Files

VisionDMD_White-Paper_Returning-Individual-Clinical-Trial-Results-Back-To-Patients_Consortium-final.pdf

Additional details

Funding

VISION DMD – VISION-DMD - Phase 2 Clinical Trials of VBP15: An Innovative Steroid-like Intervention on Duchenne Muscular Dystrophy 667078
European Commission